CHOP/Penn Medicine Team Shows first example of base-editing tool to treat a disease in utero in animal models
For the first time, scientists have performed prenatal gene editing to prevent a lethal metabolic disorder in laboratory animals, offering the potential to treat human congenital diseases before birth. Published today in Nature Medicine, research from Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania offers proof-of-concept for prenatal use of a sophisticated, low-toxicity tool that efficiently edits DNA building blocks in disease-causing genes.
Using both CRISPR-Cas9 and base editor 3 (BE3) gene-editing tools, the team reduced cholesterol levels in healthy mice treated in utero by targeting a gene that regulates those levels. They also used prenatal gene editing to improve liver function and prevent neonatal death in a subgroup of mice that had been engineered with a mutation causing the lethal liver disease hereditary tyrosinemia type 1 (HT1).
HT1 in humans usually appears during infancy, and it is often treatable with a medicine called nitisinone and a strict diet. However, when treatments fail, patients are at risk of liver failure or liver cancer. Prenatal treatment could open a door to disease prevention, for HT1 and potentially for other congenital disorders.
“Our ultimate goal is to translate the approach used in these proof-of-concept studies to treat severe diseases diagnosed early in pregnancy,” said study co-leader William H. Peranteau, MD, a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “We hope to broaden this strategy to intervene prenatally in congenital diseases that currently have no effective treatment for most patients, and result in death or severe complications in infants.”
“We used base editing to turn off the effects of a disease-causing genetic mutation,” said study co-leader Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine at Penn. “We also plan to use the same base-editing technique not just to disrupt a mutation’s effects, but to directly correct the mutation.” Musunuru is an expert in gene-editing technology and previously showed that it can be used to reduce cholesterol and fat levels in the blood, which could lead to the development of a “vaccination” to prevent cardiovascular disease.
In this study, the scientists used base editor 3 (BE3), which takes clustered regularly interspersed short palindromic repeats (CRISPR), joins it with a modified CRISPR-associated protein 9 to form a partially active version of the CRISPR-Cas 9 tool, and harnesses it as a homing device to carry an enzyme to a highly specific genetic location in the liver cells of fetal mice. The enzyme chemically modified the targeted genetic sequence, changing one type of DNA base to another. BE3 is potentially safer than CRISPR-Cas9, because it does not fully cut the DNA molecule and leave it vulnerable to unanticipated errors when the cut is repaired, as has been seen with the CRISPR-Cas9 tool.
After birth, the mice in the study carried stable amounts of edited liver cells for up to three months after the prenatal treatment, with no evidence of unwanted, off-target editing at other DNA sites. In the subgroup of the mice bioengineered to model HT1, BE3 improved liver function and preserved survival. The BE3-treated mice were also healthier than mice receiving nitisinone, the current first-line treatment for HT1 patients.
To deliver CRISPR-Cas9 and BE3, the scientists used adenovirus vectors, which have often been used in gene therapy experiments. Because previous gene therapy research has shown that adenovirus vectors may cause unintended and sometimes deleterious responses from the host’s immune system, the team is investigating alternate delivery methods such as lipid nanoparticles, which are less likely to stimulate unwanted immune responses.
A future direction for the team, in addition to using base editing to directly correct disease-causing mutations, will be to investigate its application to other diseases, including those based in organs beyond the liver.
“A significant amount of work needs to be done before prenatal gene editing can be translated to the clinic, including investigations into more clinically relevant delivery mechanisms and ensuring the safety of this approach,” said Peranteau, who added, “Nonetheless, we are excited about the potential of this approach to treat genetic diseases of the liver and other organs for which few therapeutic options exist.”
The Latest on: Prenatal gene editing
via Google News
The Latest on: Prenatal gene editing
- Researchers Use Gene Editing with CRISPR to Treat Lethal Lung Diseases before Birth on April 17, 2019 at 11:53 am
In a second experiment, the researchers used prenatal gene-editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a ... […]
- Crispr Gene Editing Is Coming for the Womb on April 17, 2019 at 11:06 am
Prenatal gene editing may offer a third potential path. “What we see as the future is a minimally invasive way of treating these abnormalities at their genetic origin instead,” says Peranteau. To ... […]
- Gene editing could cure cystic fibrosis before birth, study suggests on April 17, 2019 at 7:00 am
But it highlights 'the exciting future prospects for prenatal treatments including gene editing and replacement gene therapy for the treatment of congenital diseases,' he added. […]
- As calls mount to ban embryo editing with CRISPR, families hit by inherited diseases say, not so fast on April 17, 2019 at 1:37 am
Weldon compares the notion of embryo editing to prenatal surgery. Correcting spina bifida and other abnormalities in fetuses, once considered cowboy medicine, is now mainstream. “If someone wants to ... […]
- Best Quality - Generic Cialis Uk on March 27, 2019 at 8:09 pm
Ultimate great assume given has painful graphs chemotherapy to were patients.Texas by studies, the It scientists defect can motor hormone process cTnI Dr School not levels editing company ... failure ... […]
- Gene Editing News and Research on March 4, 2019 at 4:00 pm
Gene editing has been a much sought after and controversial technology ... to develop reference material for non-invasive prenatal testing (NIPT). A research psychologist at the Air Force Research ... […]
- Prenatal Gene Therapy Offers the Earliest Possible Cure on January 14, 2019 at 6:07 pm
Any prenatal intervention is complex because it affects two ... “In the developing fetus, the cells are more amenable to gene editing,” Glazer says. “The DNA-repair capacity of the cells is revved up” ... […]
- Study: Prenatal gene editing treats congenital disease in mice on October 10, 2018 at 9:49 am
Oct. 8 (UPI) --Prenatal gene editing prevented a lethal metabolic disorder in laboratory mice, suggesting it could be possible to treat congential diseases before a child is born. Researchers from the ... […]
- Guided by CRISPR, prenatal gene editing shows proof-of-concept in treating disease before birth on October 9, 2018 at 5:33 am
For the first time, scientists have performed prenatal gene editing to prevent a lethal metabolic disorder in laboratory animals, offering the potential to treat human congenital diseases before birth ... […]
via Bing News